Isotype
Bi-specific T-cell engager
Description
ADCC-enhanced Blinatumomab is a non-fucosylated anti-CD19 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-CD19 Blinatumomab, a biobetter by reducing fucosylation of the Fc region of Blinatumomab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia
Classification
Therapeutic antibody; biobetter
Patent
Blinatumomab was first received FDA approval in 2014. The patent will expire in the US in 2023.
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Blinatumomab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency.
Related Pathways
Its related pathways are RET signaling and B cell receptor signaling pathway (KEGG).
Function
As a co-receptor of b cell antigen receptor complex (BCR) on b lymphocytes. Lower the threshold of downstream signaling pathway activation and trigger b-cell response to antigen (PubMed: 2463100, PubMed: 1373518, PubMed: 16672701). Activating the signaling pathway leads to the activation of phosphatidylinositol 3-kinase and mobilization of intracellular Ca(2+) storage (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701). Not needed in the early steps of bone marrow B cell differentiation (PubMed:9317126). Necessary for normal differentiation of B-1 cells (similarity). Normal B cell differentiation and proliferation are required to respond to antigen challenges (PubMed: 2463100, PubMed: 1373518). Requires normal levels of serum immunoglobulins, and high-affinity antibodies produced upon antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).
Field of research
Developmental Biology antibody; Immune System antibody; Lymphocyte Marker antibody; B cell Marker antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody; Immature B Cell Marker antibody; Follicular dendritic cells antibody
Post-translational modifications
Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. Phosphorylated on tyrosine residues by LYN.
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Bi-specific T-cell engager
Antibody Clone
Blinatumomab
Description
Blinatumomab is a bispecific T-cell conjugate (BiTE) that selectively acts and guides the human immune system against tumor cells. In 2014, the product was approved by the US Food and Drug Administration under the accelerated approval program and used as a second-line treatment for Philadelphia chromosome-negative relapse or refractory acute lymphoblastic leukemia. Blinatumomab specifically targets the CD19 antigen present on B cells.
Indication
Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia
